Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Acasti Pharma Inc. ACST NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • CA • USD

SharesGrow Score
40/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Acasti Pharma Inc. (ACST) is a Biotechnology company in the Healthcare sector, currently trading at $3.37. It has a SharesGrow Score of 37/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Net income is $13M (loss), growing at -87.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $67M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 11.77 (strong liquidity). Debt-to-assets is 0%. Total assets: $72M.

Analyst outlook: 3 / 5 analysts rate ACST as buy (60%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 55/100 (Partial), Income ?/100 (Fail).

ACST SharesGrow Score Overview

50/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 55/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ACST

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
ACST: +0%/yr revenue is, -87.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ACST: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 11.77 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ACST: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
55/100
Analyst outlook: 3 / 5 analysts rate ACST as buy (60%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.98-3.6
Volume27.68K
Avg Volume (30D)33.25K
Market Cap$34.17M
Beta (1Y)1.52
Share Statistics
EPS (TTM)-0.79
Shares Outstanding$12.09M
IPO Date2012-02-07
Employees32
CEOPrashant Kohli
Financial Highlights & Ratios
Net Income$-12.77M
Total Cash$22.13M
Net Debt$-22.13M
Total Assets$71.99M
Price / Earnings (P/E)-4.3
Analyst Forecast
Rating ConsensusBuy
Analysts Covering5
Buy 60% Hold 40% Sell 0%
Company Info
CountryCA
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINCA00430K8656

Price Chart

Track all markets on TradingView
ACST
Acasti Pharma Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.98 52WK RANGE 3.60

People Also View

OCGN
OCGN
Ocugen, Inc.
$1.80
+0.56%
 CBIO
CBIO
Catalyst Biosciences, Inc.
$19.52
+8.50%
 TNXP
TNXP
Tonix Pharmaceuticals Holding Corp.
$13.35
+2.85%
 IBIO
IBIO
iBio, Inc.
$2.19
-0.45%
 ADXS
ADXS
Advaxis, Inc.
$0.60
+0.00%
 ONTX
ONTX
Onconova Therapeutics, Inc.
$1.00
-0.47%
 ABVC
ABVC
ABVC BioPharma, Inc.
$1.36
-1.45%
 DFFN
DFFN
Diffusion Pharmaceuticals Inc.
$4.40
+10.28%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message